MADISON, Wis., Nov. 2, 2020 /PRNewswire/ -- Exact Sciences Corp.
(Nasdaq: EXAS) today announced that company management will
participate in the following conferences and invited investors to
participate by webcast.
- Stifel Virtual Healthcare Conference
Fireside Chat on Monday, November 16,
2020, at 9:20 a.m. EST
- Jefferies Virtual London Healthcare Conference
Fireside Chat on Wednesday, November 18,
2020, at 2:55 p.m. EST
The webcast can be accessed in the investor relations section of
Exact Sciences' website at www.exactsciences.com.
About Exact Sciences Corp.
A leading provider of
cancer screening and diagnostic tests, Exact Sciences relentlessly
pursues smarter solutions providing the clarity to take
life-changing action, earlier. Building on the success of Cologuard
and Oncotype DX, Exact Sciences is investing in its product
pipeline to take on some of the deadliest cancers and improve
patient care. Exact Sciences unites visionary collaborators to help
advance the fight against cancer. For more information, please
visit the company's website at www.exactsciences.com, follow Exact
Sciences on Twitter @ExactSciences, or find Exact Sciences on
Facebook.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be covered by the "safe harbor" created by those sections.
Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can
generally be identified by the use of forward-looking terms such as
"believe," "expect," "may," "will," "should," "would," "could,"
"seek," "intend," "plan," "goal," "project," "estimate,"
"anticipate" or other comparable terms. All statements other than
statements of historical facts included in this news release
regarding our strategies, prospects, expectations, financial
condition, operations, costs, plans, objectives and the pending
acquisition of Thrive Earlier Detection Corporation ("Thrive") are
forward-looking statements. Examples of forward-looking statements
include, among others, statements we make regarding expected future
operating results, anticipated results of our sales, marketing and
patient adherence efforts, expectations concerning payer
reimbursement, the anticipated results of our product development
efforts, the anticipated benefits of the pending acquisition of
Thrive, including estimated synergies and other financial impacts,
and the expected timing of completion of the transaction.
Forward-looking statements are neither historical facts nor
assurances of future performance or events. Instead, they are based
only on current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Actual results, conditions and
events may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause actual results, conditions and events to differ materially
from those indicated in the forward-looking statements include,
among others, the following: uncertainties associated with the
coronavirus (COVID-19) pandemic, including its possible effects on
our operations, including our supply chain, and the demand for our
products and services; our ability to efficiently and flexibly
manage our business amid uncertainties related to COVID-19; our
ability to successfully and profitably market our products and
services; the acceptance of our products and services by patients
and healthcare providers; our ability to meet demand for our
products and services; the success of our efforts to facilitate
patient access to Cologuard via telehealth; the willingness of
health insurance companies and other payers to cover our products
and services and adequately reimburse us for such products and
services; the amount and nature of competition for our products and
services; the effects of the adoption, modification or repeal of
any law, rule, order, interpretation or policy relating to the
healthcare system, including without limitation as a result of any
judicial, executive or legislative action; the effects of changes
in pricing, coverage and reimbursement for our products and
services, including without limitation as a result of the
Protecting Access to Medicare Act of 2014; recommendations,
guidelines and quality metrics issued by various organizations such
as the U.S. Preventive Services Task Force, the American Society of
Clinical Oncology, the American Cancer Society, and the National
Committee for Quality Assurance regarding cancer screening or our
products and services; our ability to successfully develop new
products and services and assess potential market opportunities;
our ability to effectively enter into and utilize strategic
partnerships, such as through our Promotion Agreement with Pfizer,
Inc., and acquisitions; our success establishing and maintaining
collaborative, licensing and supplier arrangements; our ability,
and the ability of Thrive and Base Genomics Limited ("Base"), to
maintain regulatory approvals and comply with applicable
regulations; our ability to manage an international business and
our expectations regarding our international expansion and
opportunities; the potential effects of foreign currency exchange
rate fluctuations and our efforts to hedge such effects; the
possibility that the anticipated benefits from our business
acquisitions (including the pending acquisition of Thrive and
recent acquisition of Base) cannot be realized in full or at all or
may take longer to realize than expected; the possibility that
costs or difficulties related to the integration of acquired
businesses' (including Thrive's and Base's) operations will be
greater than expected and the possibility of disruptions to our
business during integration efforts and strain on management time
and resources; the outcome of any litigation, government
investigations, enforcement actions or other legal proceedings; the
ability of the Company and Thrive to receive the required the
required regulatory approvals for the pending merger and to satisfy
the conditions to the closing of the transaction on a timely basis
or at all; the occurrence of events that may give rise to a right
of one or both of the Company and Thrive to terminate the merger
agreement; possible negative effects of the announcement or the
consummation of the pending acquisition of Thrive or recent
acquisition of Base on the market price of our common stock and/or
on our and/or Thrive's or Base's respective businesses, financial
conditions, results of operations and financial performance;
significant transaction costs and/or unknown liabilities; risks
associated with contracts containing consent and/or other
provisions that may be triggered by the pending acquisition of
Thrive or the recent acquisition of Base; risks associated with
potential transaction-related litigation; the ability of Thrive,
Base and the combined company to retain and hire key personnel; and
the other risks and uncertainties described in the Risk Factors and
in Management's Discussion and Analysis of Financial Condition and
Results of Operations sections of our most recently filed Annual
Report on Form 10-K and our subsequently filed Quarterly Reports on
Form 10-Q. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
Megan
Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
View original content to download
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-november-investor-conferences-301164451.html
SOURCE EXACT SCIENCES CORP
